Meridian Small Cap Growth Fund on Veracyte, Inc.
Thesis
Meridian owns Veracyte for durable, volume-driven genomic-testing revenue, an expanding diagnostic menu, and a competitive moat built on more than a decade of proprietary clinical evidence. Strong results and raised full-year guidance were supported by double-digit Decipher volume growth and better Afirma performance after a workflow upgrade reduced no-result rates. Planned launches of Prosigna in breast cancer and TrueMRD in bladder cancer, together with continued clinical-data generation, support the fund's view of a multi-year growth runway.
“We own it for its durable, volume-driven testing revenue, expanding menu, and a defensible competitive moat built over more than a decade of evidence generation.”